

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

Granzyme B Monoclonal Antibody (GB11), APC

RRID:AB_2536539

Type: Antibody

Proper Citation

Thermo Fisher Scientific Cat# GRB05, RRID:AB_2536539

Antibody Information

URL: http://antibodyregistry.org/AB_2536539

Proper Citation: Thermo Fisher Scientific Cat# GRB05, RRID:AB_2536539

Target Antigen: Granzyme B

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow (Assay-dependent)

Antibody Name: Granzyme B Monoclonal Antibody (GB11), APC

Description: This monoclonal targets Granzyme B

Target Organism: human

Clone ID: Clone GB11

Defining Citation: [PMID:24762408](#), [PMID:17312126](#), [PMID:16357323](#), [PMID:25954597](#), [PMID:17569889](#), [PMID:22006977](#)

Antibody ID: AB_2536539

Vendor: Thermo Fisher Scientific

Catalog Number: GRB05

Record Creation Time: 20231110T035505+0000

Record Last Update: 20260831T211645+0000

Ratings and Alerts

No rating or validation information has been found for Granzyme B Monoclonal Antibody (GB11), APC.

No alerts have been found for Granzyme B Monoclonal Antibody (GB11), APC.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Sakrepatna Nagaraj A, et al. (2026) Ex Vivo Immuno-Oncology Platform Reveals Spatial T-cell Infiltration Patterns Linked to ATR Inhibition Responses in High-Grade Serous Ovarian Cancer. *Cancer immunology research*, 14(4), 625.

Yu J, et al. (2026) 6-Hydroxydopamine promotes antitumor immunity through macrophage remodeling beyond sympathetic ablation. *Neuron*, 114(14), 2532.

Vendramin R, et al. (2026) Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome. *Immunity*, 59(5), 1398.

Praiss AM, et al. (2025) Evolution of tumor stress response during cytoreductive surgery for ovarian cancer. *iScience*, 28(5), 112317.

Osorio JC, et al. (2025) Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer. *Cancer cell*.

Launonen IM, et al. (2024) Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer. *Cancer cell*, 42(12), 2045.

Van Der Byl W, et al. (2024) The CD8+ T cell tolerance checkpoint triggers a distinct differentiation state defined by protein translation defects. *Immunity*, 57(6), 1324.

Pedde AM, et al. (2024) Tissue-colonizing disseminated tumor cells secrete prostaglandin E2 to promote NK cell dysfunction and evade anti-metastatic immunity. *Cell reports*, 43(11), 114855.

Bayerl F, et al. (2023) Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses. *Immunity*, 56(6), 1341.

Meiser P, et al. (2023) A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity. *Cancer cell*, 41(8), 1498.

Nixon BG, et al. (2022) Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer. *Immunity*, 55(11), 2044.

Chen Y, et al. (2022) Oncogenic collagen I homotrimers from cancer cells bind to $\alpha 1$ integrin and impact tumor microbiome and immunity to promote pancreatic cancer. *Cancer cell*, 40(8), 818.

Zhao H, et al. (2021) Genome-wide fitness gene identification reveals Roquin as a potent suppressor of CD8 T cell expansion and anti-tumor immunity. *Cell reports*, 37(10), 110083.

Dege C, et al. (2020) Potently Cytotoxic Natural Killer Cells Initially Emerge from Erythro-Myeloid Progenitors during Mammalian Development. *Developmental cell*, 53(2), 229.

Wlezińska A, et al. (2020) Regulatory T Cells Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4⁺ T Cells. *Immunity*, 52(1), 151.

Smith NL, et al. (2018) Developmental Origin Governs CD8⁺ T Cell Fate Decisions during Infection. *Cell*, 174(1), 117.